Rezultati - Eugene Balagula

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP)

    Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-R... od Linda Stein Gold, Michael Sebastian, Eugene Balagula, Brandon Becker, Yichen Zhong, Rachel Dyme, Michael DeRosa, Scott Fretzin, Andreas Pinter, C.E.M. Griffiths

    Izdano 2025
    Polni tekst
    Artigo
    Dodaj v priljubljene
    Shranjeno v:

Iskalna orodja: